Aldostefano Porcari
Overview
Explore the profile of Aldostefano Porcari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
860
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Argiro A, Biagioni G, Mazzoni C, Zampieri M, Allinovi M, Musumeci B, et al.
Int J Cardiol
. 2025 Feb;
424:133027.
PMID: 39900190
Background: Hypertension and diabetes may increase the risk of adverse events in the general population and patients with cardiomyopathies, however, their role in patients with cardiac amyloidosis (CA) is still...
2.
Porcari A, Fontana M, Riefolo M
Circ Heart Fail
. 2025 Jan;
18(2):e012652.
PMID: 39866120
No abstract available.
3.
Emdin M, Aimo A, Ferrari Chen Y, Merlo M, Porcari A, Vergaro G, et al.
J Cardiovasc Med (Hagerstown)
. 2025 Jan;
26(2):102-105.
PMID: 39841915
Diagnosing cardiac amyloidosis (CA) is challenging because of its phenotypic heterogeneity, multiorgan involvement requiring interaction among experts in different specialties and subspecialties, lack of a single noninvasive diagnostic tool, and...
4.
Porcari A, Razvi Y, Cappelli F, Nitsche C, Serenelli M, Longhi S, et al.
JAMA Cardiol
. 2025 Jan;
PMID: 39841451
Importance: Patients with transthyretin (ATTR) cardiac amyloid infiltration are increasingly diagnosed at earlier disease stages with no heart failure (HF) symptoms and a wide range of cardiac amyloid infiltration. Objective:...
5.
Argiro A, Zampieri M, Mazzoni C, Fumagalli C, Baccini M, Mattei A, et al.
ESC Heart Fail
. 2024 Dec;
PMID: 39665521
Aims: This study aimed to evaluate the change of the main electrocardiographic (ECG) characteristics and their prognostic role across the main subtypes of cardiac amyloidosis [light-chain amyloidosis (AL) and hereditary...
6.
Porcari A, Chimenti C, Merlo M, Musca F, Vergaro G, Iacoviello M, et al.
G Ital Cardiol (Rome)
. 2024 Nov;
25(12):900-920.
PMID: 39588628
The perspective on cardiac amyloidosis has deeply changed over the last 10 years following major advances in diagnosis and treatment options. This heterogeneous disease requires the interaction among experts of...
7.
Ioannou A, Razvi Y, Porcari A, Rauf M, Martinez-Naharro A, Venneri L, et al.
JAMA Cardiol
. 2024 Nov;
10(1):50-58.
PMID: 39550765
Importance: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiomyopathy that commonly presents with concomitant chronic kidney disease. Chronic kidney dysfunction is associated with worse outcomes, but the prognostic value of...
8.
Sharrack N, Knott K, Gulsin G, Kotecha T, Brown L, Yeo J, et al.
Sci Rep
. 2024 Nov;
14(1):27280.
PMID: 39516499
Metformin is an antihyperglycemic used to treat type 2 diabetes mellitus (T2DM). Patients with T2DM are at increased risk of cardiovascular disease. We explored the association between metformin use and...
9.
Porcari A, Gillmore J, Ioannou A, Solomon S, Fontana M
J Am Coll Cardiol
. 2024 Nov;
84(20):e291.
PMID: 39505423
No abstract available.
10.
Netti L, Ioannou A, Martinez-Naharro A, Razvi Y, Porcari A, Venneri L, et al.
Eur J Heart Fail
. 2024 Oct;
PMID: 39422337
Aims: Cardiac amyloidosis (CA) is characterized by deposition of amyloid fibrils within the extracellular space, causing disarray of the myocardial structure and capillary architecture. This study aims to characterize the...